OKYO PHARMA LTD

OKYO Pharma insider buy: CEO Patil Rajkumar V. snaps up 3,363 shares as Phase 3 trial looms, signaling confidence and potential upside for investors.

OKYO Pharma insiders buy shares, signaling confidence in its Phase 3 eye‑pain drug; learn how this may spark a rally amid cash‑flow challenges.

OKYO Pharma insider buying shows confidence in a pending Phase‑3 trial—what this means for investors and volatility.

OKYO Pharma insiders buying 25,000 shares ahead of Phase 3 urcosimod trial—signaling confidence and a potential upside for investors.

OKYO Pharma insiders hold long‑term options, signaling confidence in future growth while signaling potential dilution – a strategic view that could shape investors’ outlook as the company advances its pre‑clinical pipeline and seeks financing.

OKYO Pharma insider report: CERRONE GABRIELE M keeps a 10‑million‑share stake, valuing his holding at ~$17M. The move signals confidence in pre‑clinical plans and a potential price rally when key milestones hit.

Insider confidence fuels OKYO Pharma’s eye‑disease pipeline—Jacob Gary S. retains 108,920 shares and options, signaling potential milestones and market upside despite a current price‑sentiment lag.